...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
【24h】

A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.

机译：一项为期2年的纵向放射学研究，研究了双膦酸盐（瑞斯膦酸盐）对骨关节炎膝盖患者软骨下骨丢失的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). METHODS: Initially, 100 patients were randomly selected from each treatment group (each N approximately 300) comprising placebo and RIS 5 mg/day, 15 mg/day and 50 mg/week from a double blind, multi-centre, placebo-controlled, 2 yr investigation of OA knee patients in North America. Using fluoroscopic semi-flexed standard radiography, baseline and exit knee radiographs were digitized by laser scanner. Following computerized measurement of minimum medial compartment joint space width, each group was subdivided into joint space narrowing (JSN) non-progressor or JSN-progressor (JSN >or=0.6 mm measured at any point post-baseline). Computerized method of fractal signature analysis (FSA) quantified longitudinal changes separately in horizontal and vertical trabeculae in region of interest (three-fourth width of tibial compartment x 6 mm height) in the medial compartment. Following the initial study, all JSN-progressor knees within the entire patient cohort (N = 1232) were similarly analysed. RESULTS: OA knees in JSN non-progressor group had a slight decrease in FSA for vertical and horizontal trabeculae and showed no drug effect. In JSN-progressor knees, bone loss was greater in both placebo and RIS 5 mg/day groups compared with those in RIS 15 mg/day group in which trabeculae were retained, and in the RIS 50 mg/week group in which the vertical trabecular number increased significantly (P < 0.05). CONCLUSION: This preliminary study showed that patients with marked cartilage loss (JSN>or=0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA.
机译：目的：确定瑞斯膦酸盐（RIS）是否能减慢胫骨近端内侧小梁的骨小梁丢失，这是进行性膝骨关节炎（OA）患者的特征。方法：最初，从每个治疗组中随机抽取100名患者（每组N约300），分别由双盲，多中心，安慰剂对照的安慰剂和RIS分别为5 mg /天，15 mg /天和50 mg /周。对北美OA膝关节患者进行的2年调查。使用荧光半弯曲标准放射线照相术，通过激光扫描仪将基线和出口膝部照相术数字化。在计算机测量了内侧隔间的最小关节间隙宽度后，将每组细分为关节间隙变窄（JSN）非渐进性或JSN渐进性（在基线后的任意点测得的JSN>或= 0.6 mm）。分形特征分析（FSA）的计算机化方法分别量化了内侧隔室中感兴趣区域（胫骨隔室的四分之三宽度×6 mm高）中水平和垂直小梁的纵向变化。在最初的研究之后，对整个患者队列（N = 1232）中的所有JSN-progressor膝盖进行了类似的分析。结果：JSN非前进步伐组的OA膝对于垂直和水平小梁的FSA略有下降，并且没有药物作用。与保留小梁的RIS 15 mg /天组和垂直小梁的RIS 50 mg /周组相比，在JSN前膝膝关节中，安慰剂组和RIS 5 mg / day组的骨丢失均更大。数量显着增加（P <0.05）。结论：这项初步研究表明，接受RIS 15 mg / day的明显软骨损失（JSN>或= 0.6 mm）的患者保留了垂直小梁结构，而接受RIS 50 mg / week的患者增加了垂直小梁数量，从而保持了小梁的结构完整性。膝OA骨软骨下骨。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号